Plasminogen Activator Inhibitor Type 1, Stable Mutant Protein

Plasminogen Activator Inhibitor 1 (PAI-1) is a glycoprotein found in plasma that is implicated in the processes of angiogenesis, hemostasis, tumor metastasis, fibrionlysis, ovulation, embryonic development and inflammation (1). The elevation of PAI-1 has shown to correlate with the prognosis of many cancers including breast cancer (2,3,4). PAI-1 is activated by the glycoprotein vitronectin. Vitronectin binds to PAI-1 and modulates fibrinolysis and cell migration (5). This binding has proven to be an important inhibitor of the activated form of protein C (APC) (6).
Epitope Location:
N-Terminal Cysteine
Solubility:
>2mg/ml and <5mg/ml
Form:
Supplied as a liquid in 0.05M sodium phosphate; 0.1M sodium chloride; 1mM EDTA; 1mM DDT; pH 6.6
Purity:
>98% pure by SDS PAGE 95 ± 5% active by uPA titration
Concentration:
2.9mg/ml
Kinetic Data:
Second order rate constants for inhibition of:
uPA = 6.3 X 10e6 M^-1s^-1
tPA = 5.7 X 10e6 M^-1s^-1
Storage and Stability:
May be stored at 4 degree C for short-term only. For long-term storage, aliquot to avoid repeated freezing and thawing and freeze at -70 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquots are stable for at least 12 months

Small volumes of Plasminogen Activator Inhibitor Type 1, stable mutant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS634957 is a protein targeting Plasminogen Activator Inhibitor Type 1, stable mutant. Also known as Plasminogen Activator Inhibitor Type 1, Human, stable mutant (PAI-1).